💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Selumetinib

CHEMBL1614701 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
457.7 g/mol
LogP
3.6
Phase
4

This oral medication targets a specific signaling pathway called MEK that cancer cells rely on to grow and divide uncontrollably. It is approved for children with neurofibromatosis type 1 and inoperable plexiform neurofibromas, and is being studied in melanoma and other MEK-driven cancers.

Peso molecular

457,7000 g/mol

LogP

3,60

TPSA

88,40 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Anestesiología Artritis reumatoide Asma Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Degeneración macular relacionada con la edad Dermatitis atópica Dermatología Diabetes tipo 2 Dolor crónico Endocrinología Endometriosis Enfermedad cardiovascular Enfermedad de Alzheimer Enfermedad del hígado graso no alcohólico Enfermedad de Parkinson Enfermedad infecciosa Enfermedad inflamatoria intestinal Enfermedad por reflujo gastroesofágico Enfermedad pulmonar obstructiva crónica Enfermedad renal crónica Enfermedad respiratoria Epilepsia Esclerosis múltiple Esquizofrenia Fibrilación auricular Gastroenterología Glaucoma Gota Hematología Hepatitis C Hepatología Hiperlipidemia Hiperplasia prostática benigna Hipertensión Ictus Inmunología Insomnio Insuficiencia cardíaca Leucemia Linfoma Lupus eritematoso sistémico Malaria Manejo del dolor Medicina de trasplantes Melanoma Migraña Nefrología Neurología Obesidad Obstetricia y ginecología Oftalmología Oncología Osteoporosis Psiquiatría Psoriasis Reumatología Trastorno bipolar Trastorno de ansiedad generalizada Trastorno depresivo mayor Trombosis venosa profunda / Embolia pulmonar Tuberculosis Urología VIH/sida

Mecanismo de acción

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21

                

                

                
                

                    
InChI

                    
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H15BrClFN4O3

                    

                    
                    

                        
HBD / HBA

                        
3 / 6

                    

                    
                    

                        
Enlaces Rotables

                        
6

                    

                    
                    
                    

                        
Átomos Pesados

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
This oral medication targets a specific signaling pathway called MEK that cancer cells rely on to grow and divide uncontrollably. It is approved for children with neurofibromatosis type 1 and inoperable plexiform neurofibromas, and is being studied in melanoma and other MEK-driven cancers.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Selumetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1614701.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10127622.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.